Health Economics›Non-small cell lung cancer nonsquamous›Advanced or metastatic disease first-line

Advanced or metastatic disease first-line

Non-small cell lung cancer nonsquamous · 32 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 23 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Carboplatin, Pemetrexed, Pembrolizumab Variant #01	—	R 83 725	21d	8.8 mo	21.3 mo	13	R 1 088 430 PFS proxy	7
Cisplatin, Pemetrexed, Pembrolizumab Variant #01	—	R 83 075	21d	8.8 mo	22.0 mo	13	R 1 079 973 PFS proxy	6
Carboplatin, Pemetrexed, Ipilimumab, Nivolumab Variant #01 Partial	—	R 80 353	21d	—	15.8 mo	—	—	1
Cisplatin, Pemetrexed, Ipilimumab, Nivolumab Variant #01 Partial	—	R 79 703	21d	—	15.8 mo	—	—	1
Ipilimumab and Nivolumab Variant #01 Partial	—	R 78 615	42d	~11.5 mo	~29.2 mo	~9	~R 707 538 PFS proxy · indirect	13
Carboplatin and nab-Paclitaxel (CnP) and Atezolizumab Variant #01	—	R 78 195	21d	—	18.6 mo	—	—	1
ABCP Variant #01	—	R 62 322	21d	8.9 mo	19.0 mo	13	R 810 191 PFS proxy	3
Carboplatin and Paclitaxel (CP) and Bevacizumab Variant #12	—	R 45 174	21d	8.2 mo	14.7 mo	12	R 542 091 PFS proxy	8
Carboplatin and nab-Paclitaxel (CnP) Variant #01	—	R 38 912	21d	—	13.9 mo	—	—	1
Carboplatin, Pemetrexed, Atezolizumab Variant #01	—	R 33 198	21d	7.9 mo	17.5 mo	12	R 398 375 PFS proxy	2
Cisplatin, Pemetrexed, Atezolizumab Variant #01	—	R 32 342	21d	8.0 mo	17.5 mo	12	R 388 107 PFS proxy	1
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	20.2 mo	—	30	R 937 639 PFS proxy	1
Carboplatin and Paclitaxel (CP), Bevacizumab, Nivolumab Variant #01 Partial	—	R 31 241	21d	11.4 mo	31.6 mo	17	R 531 099 PFS proxy	3
Cisplatin, Pemetrexed, Bevacizumab Variant #01	—	R 29 711	21d	5.6 mo	—	9	R 267 397 PFS proxy	2
Cisplatin and Gemcitabine (GC) and Bevacizumab Variant #01	—	R 18 265	21d	—	—	—	—	2
Carboplatin, Pemetrexed, Bevacizumab Variant #01	—	R 16 050	21d	6.8 mo	12.6 mo	10	R 160 498 PFS proxy	2
Cisplatin and Gemcitabine (GC) Variant #34	—	R 15 338	56d	—	17.7 mo	—	—	2
Gefitinib monotherapy Variant #01	—	R 8 556	28d	8.4 mo	20.6 mo	10	R 85 556 PFS proxy	4
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	6.1 mo	14.2 mo	9	R 45 276 PFS proxy	7
Carboplatin and Gemcitabine (GCb) Variant #01	—	R 3 663	21d	~5.3 mo	~10.0 mo	~8	~R 29 304 PFS proxy · indirect	18
Carboplatin and Docetaxel (DCb) Variant #01	—	R 3 300	21d	—	14.7 mo	—	—	—
Carboplatin, Pemetrexed, Camrelizumab Variant #01 Partial	—	R 1 738	21d	11.3 mo	27.1 mo	17	R 29 549 PFS proxy	3
Carboplatin, Pemetrexed, Cemiplimab Variant #01 Partial	—	R 1 738	21d	—	21.5 mo	—	—	2
Carboplatin, Pemetrexed, Sintilimab Variant #01 Partial	—	R 1 738	21d	8.9 mo	24.2 mo	13	R 22 596 PFS proxy	2
Carboplatin, Pemetrexed, Sugemalimab Variant #01 Partial	—	R 1 738	21d	9.0 mo	25.3 mo	14	R 24 334 PFS proxy	4
Carboplatin, Pemetrexed, Tislelizumab Variant #01 Partial	—	R 1 738	21d	9.8 mo	—	15	R 26 072 PFS proxy	1
Cisplatin, Pemetrexed, Tislelizumab Variant #01 Partial	—	R 1 088	21d	9.8 mo	—	15	R 16 314 PFS proxy	1
Cisplatin and Pemetrexed Variant #01	—	R 1 088	21d	5.0 mo	13.4 mo	8	R 8 701 PFS proxy	12
Cisplatin, Pemetrexed, Cemiplimab Variant #01 Partial	—	R 1 088	21d	—	21.5 mo	—	—	2
Cisplatin, Pemetrexed, Sintilimab Variant #01 Partial	—	R 1 088	21d	8.9 mo	24.2 mo	13	R 14 139 PFS proxy	2
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	—	R 449	21d	4.4 mo	—	7	R 3 144 PFS proxy	—
Carboplatin and Pemetrexed N/A - secondary systemic drug	—	R 52	21d	5.1 mo	14.9 mo	8	R 417 PFS proxy	18

32 of 32 regimens shown